BofA reinstated coverage of Regeneron (REGN) with an Underperform rating and $565 price target The firm calls Regeneron a “high-quality company,” with “lots to like generally,” but thinks Eylea, its lead franchise, erodes faster and harder than consensus. Despite a pullback in shares, the premium remains “too big,” especially given the firm’s below-consensus 2025 EPS view, the analyst added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio